Kamada Ltd. filings document a foreign private issuer reporting on a global biopharmaceutical business focused on specialty plasma-derived therapies and marketed products for rare and serious conditions. Recent Form 6-K reports include exhibits on financial results, annual guidance, investor presentations, product-supply tenders, and FDA approval of a plasma collection center.
The filings also record ordinary-share dividend actions, withholding-tax procedures tied to Israeli tax rules, and incorporation of certain current reports by reference into Form S-8 registration statements. Kamada files as a Form 20-F issuer, with disclosures covering governance, capital-return actions, commercial portfolio performance and regulatory events affecting plasma collection and product supply.
Kamada Ltd director Leon Recanati reported a series of administrative transactions in employee stock options held indirectly through a trustee under the company’s 2011 Share Award Plan. On April 7, 2026, he received multiple option grants (code A) and simultaneously returned matching options to the issuer (code D) with slightly different exercise prices.
Footnotes explain that exercise prices in U.S. dollars are convenience translations from NIS and were adjusted under the plan following a cash dividend declared on March 11, 2026, with no other changes to the awards’ terms. The options vest in four equal annual installments, and there were no open‑market purchases or sales of ordinary shares disclosed.
Kamada Ltd director Dekel Benjamin reported routine employee stock option adjustments held indirectly through a trustee under the company’s 2011 Share Award Plan. On the same date, he both received and returned options covering 4,000 ordinary shares in offsetting grant and disposition entries.
The options carry exercise prices shown in U.S. dollars as a convenience from NIS and were adjusted under the plan following a cash dividend declared on March 11, 2026. The award vests in four equal annual installments from the grant date and expires on March 7, 2030, leaving 4,000 options reported as outstanding after these transactions.
KAMADA LTD VP and General Counsel Nir Livneh reported a series of employee stock option grants and related option adjustments held via a trustee under the company’s 2011 Share Award Plan. The transactions show awards of options to buy Ordinary Shares at exercise prices stated in U.S. dollars for convenience, paired with corresponding dispositions of options back to the issuer reflecting adjusted exercise prices following a cash dividend distribution. The options vest in four equal annual installments from their grant dates and have expiration dates ranging from late 2029 to late 2035, indicating long-term, compensation-related equity exposure rather than open-market share trading.
Kamada Ltd Chief Financial Officer Chaime Orlev reported a series of administrative option adjustments under the company’s 2011 Share Award Plan. All entries relate to employee stock options held indirectly by a trustee, not to open-market share purchases or sales.
The filing shows nine grants and nine matching dispositions of options on ordinary shares, with exercise prices such as $5.87, $5.90, $6.12, $6.15, $7.25 and $7.50 per share presented in U.S. dollars. Footnotes explain that exercise prices were adjusted under the plan following a cash dividend declared on March 11, 2026, and that options vest in four equal annual installments.
Kamada Ltd director and 10% owner Davidi Ishay reported multiple compensation-related option adjustments held by a trustee under the company’s 2011 Share Award Plan. The Form 4 shows paired acquisitions and dispositions of employee stock options, with 16 derivative transactions and no open‑market share purchases or sales.
The options cover blocks of 6,625 and 7,500 ordinary shares at exercise prices between $5.87 and $7.48, with expirations in 2026 and 2029. Footnotes state that exercise prices were adjusted for a cash dividend declared on March 11, 2026, and that vesting occurs in four equal annual installments from each grant date.
Kamada Ltd VP Regulatory Affairs Orit Pinchuk reported a series of employee stock option adjustments and grants held indirectly by a trustee under the company’s 2011 Share Award Plan. On April 7, 2026, she was granted several blocks of 15,000 employee stock options each, with exercise prices of $5.87 and $7.25 per ordinary share and expirations extending to October 22, 2035. Matching dispositions of 15,000 options each back to the issuer at exercise prices of $6.12 and $7.50 were also reported. A footnote explains the exercise prices were adjusted under the 2011 Share Award Plan in connection with a cash dividend declared on March 11, 2026, with no other changes to the option terms, and that the options vest in four equal annual installments.
Kamada Ltd director David Tsur, through a trustee under the company’s 2011 Share Award Plan, reported a series of routine option award adjustments on Employee Stock Options (right to buy) linked to Ordinary Shares. The filing shows multiple grant acquisitions and matching dispositions back to the issuer at different exercise prices, leaving each award with 6,625 or 7,500 options outstanding per line. Exercise prices are stated in U.S. dollars as a convenience translation from NIS and were adjusted under the plan following a cash dividend declared by the board. The options vest in four equal annual installments from each grant date and carry expiration dates in 2026 and 2029.
Kamada Ltd VP of Plasma Operations Beladev Shavit reported routine employee stock option adjustments held through a trustee under the company’s 2011 Share Award Plan. The Form 4 shows five grants or awards and five matching dispositions to the issuer, each involving 15,000 options for Ordinary Shares.
Exercise prices, presented in U.S. dollars, range from $5.87 to $7.50 per share and were adjusted under the plan after a cash dividend declared on March 11, 2026. The options vest in four equal annual installments from the grant date and some series carry expiration dates as late as 2035.
KAMADA LTD VP of Operations Nir Eran reported compensation-related option adjustments held through a trustee under the company’s 2011 Share Award Plan. On April 7, 2026, he received grants of a total of 112,500 Employee Stock Options to buy Ordinary Shares and surrendered 112,500 options back to the company.
The grants include tranches of 22,500 options at exercise prices of $5.87 and $7.25 per share, with corresponding dispositions of 22,500 options at $6.12 and $7.50. Footnotes state exercise prices are translated from NIS and were adjusted under the 2011 Share Award Plan in connection with a cash dividend distribution, with all other award terms unchanged. The options vest in four equal annual installments starting on the grant date anniversaries and some tranches expire on August 28, 2028 while others expire on October 22, 2035.
Kamada Ltd VP Quality Yael Brenner reported compensation-related option adjustments rather than open‑market trades. On April 7, 2026, she was granted several tranches of employee stock options for 15,000 underlying ordinary shares, held indirectly by a trustee under the company’s 2011 Share Award Plan.
The filing shows paired entries where options with exercise prices of $6.12 and $7.50 were disposed of to the issuer and replaced with options at adjusted exercise prices of $5.87 and $7.25. A footnote explains the exercise prices were adjusted under the plan following a cash dividend declared on March 11, 2026, with no other changes to award terms. The options vest in four equal annual installments.